You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Recruiting
  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous
  • Nagoya, Japan
  • +2 more
2021-11-16
Nov 16, 2021
C
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Recruiting
  • Lymphoma, T-Cell, Peripheral
  • Osaka, Japan
    Nihon Seimei Hospital
2021-06-01
Jun 1, 2021
N
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas - 2022
Completed
  • Lymphoma, Large-Cell, Anaplasitc
  • +4 more
  • Anti-CD30-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022
F
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
2021-12-03
Dec 3, 2021
P
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
Not yet recruiting
  • T-cell Lymphoma
  • Tucidinostat, Azacitidine combined with CHOP
  • (no location specified)
2021-10-09
Oct 9, 2021
U
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma - 2021
Completed
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • London, United Kingdom
    University College London Hospital
2021-10-01
Oct 1, 2021
T
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-12-21
Dec 21, 2021
K
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +4 more
  • Cincinnati, Ohio
    The Christ Hospital Cancer Center
2022-02-08
Feb 8, 2022
H
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021
U
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
2022-02-03
Feb 3, 2022
L
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
2022-02-15
Feb 15, 2022
D
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Recruiting
  • Cutaneous T Cell Lymphoma
  • Peripheral T Cell Lymphoma
  • Microdevices
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-06-22
Jun 22, 2021
N
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Recruiting
  • Peripheral T-cell Lymphomas
  • +2 more
  • Bethesda, Maryland
  • +1 more
2022-04-07
Apr 7, 2022
C
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Not yet recruiting
  • Lymphoma, T-Cell, Peripheral
  • Adcetris 50 MG Injection
  • +4 more
  • Brno, Czechia
  • +6 more
2021-08-26
Aug 26, 2021
N
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
W
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
2022-02-14
Feb 14, 2022
P
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +2 more
  • Lenalidomide 15mg
  • Brentuximab Vedotin 1.8 mg/Kg
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
2020-09-29
Sep 29, 2020
O
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
2022-02-21
Feb 21, 2022
T
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
2021-09-29
Sep 29, 2021
S
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
2021-09-20
Sep 20, 2021
U
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
2022-03-04
Mar 4, 2022
K
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 - 2012
Completed
Has Results
  • Peripheral T-cell Lymphoma
  • Cutaneous T-cell Lymphoma
  • KW-0761
  • Stanford, California
    Stanford University
2020-12-03
Dec 3, 2020
U
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders - 2020
Terminated
  • Lymphoma, T-Cell, Cutaneous
  • +6 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
2021-01-20
Jan 20, 2021
M
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory PTCL
Recruiting
  • Peripheral T Cell Lymphoma (PTCL)
  • MT-101
  • MT-101 + Conditioning (Lymphodepleting) Chemotherapy
  • Duarte, California
  • +2 more
2022-03-18
Mar 18, 2022
R
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Active, not recruiting
Has Results
  • Peripheral T Cell Lymphoma
  • Ann Arbor, Michigan
  • +2 more
2021-08-13
Aug 13, 2021